INDV
Indivior Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$34.88
−2.27%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$35.36
From 52W high−16.61%
Volume4.44M
Market cap$4.12B
P/E (TTM)12.3x
P/S (TTM)3.1x
Div yield—
Key dataSep 18, 2026
Open
$35.36
From 52W high
−16.61%
Volume
4.44M
Market cap
$4.12B
ValuationView details →
P/E (Fwd)
7.7x
EV/EBITDA
10.2x
P/E (TTM)
12.3x
RSI (14)
40.7
MomentumView details →
1D Return
−2.27%
YTD Return
−3.33%
SummaryUpdated Jun 1, 2026
Indivior PLC (NASDAQ:INDV) is a specialty pharmaceutical company founded in 2014 through a spin-off from Reckitt Benckiser Group. Headquartered in North Chesterfield, Virginia, the company focuses exclusively on developing and commercializing treatments for substance use disorders, particularly opioid use disorder (OUD). Since its inception, Indivior has evolved from a diversified pharmaceutical company into a specialized addiction treatment provider, divesting non-core assets to concentrate on addressing the ongoing opioid crisis through innovative medication-assisted treatment solutions.
Similar companies
Latest newsMore news →
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a definitive agreement to merge in an all-stock merger of equals, creating a combined CNS biopharmaceutical company named Supernus, Inc.48d agoIndivior Pharmaceuticals repurchased shares totaling $175 million in Q2 2026 at an average price of $37.52 per share, bringing year-to-date repurchases to $300 million.49d agoIndivior Pharmaceuticals reported Q2 2026 total net revenue of $343 million, up 14% year-over-year, with GAAP net income of $122 million and diluted EPS of $0.98.49d ago